Sh-Polypeptide-86 for Hair Regrowth

Evidence Review created on 08/04/2026 using AI4L + evidence-mcp / Opus 4.8

Also known as: Follistatin, Synthetic Follistatin, Recombinant Human Follistatin, FST

Motivation

Sh-Polypeptide-86 (a laboratory-made copy of a natural human protein called follistatin) is an ingredient that has begun appearing in premium scalp serums marketed for thicker, fuller hair. In the body, follistatin acts as a brake on other proteins that tell hair follicles to rest or shrink. The idea behind putting it in a serum is simple: if these “stop growing” signals can be blocked at the scalp, dormant follicles might be nudged back into an active growing phase.

The protein first drew scientific attention through muscle and fertility research, and its link to hair comes largely from animal studies and one small early human study of an injected mixture that contained it. More recently it has been folded into multi-ingredient “peptide” serums promoted within longevity and self-optimization circles, which has sharply raised consumer interest well ahead of the evidence.

This review examines what is actually known about Sh-Polypeptide-86 as a hair-regrowth ingredient: how it is thought to work, what the human and animal evidence does and does not show, the practical hurdles of delivering a large protein through the scalp, and the safety questions that remain open.

Benefits - Risks - Protocol - Conclusion

A curated set of high-level overviews and expert commentary that place Sh-Polypeptide-86 and follistatin in the broader context of hair-loss biology and peptide-based hair care.

Note: Of the priority experts, only Peter Attia has published directly relevant, name-level content on the pharmacology of hair loss and peptides. Independent web and on-site searches of Rhonda Patrick (foundmyfitness.com), Andrew Huberman (hubermanlab.com), Chris Kresser (chriskresser.com), and Life Extension (lifeextension.com) did not return material that discusses follistatin or Sh-Polypeptide-86 specifically in a hair-regrowth context, so no item from those sources is included.

Grokipedia

  • Follistatin - Grokipedia

    The primary Grokipedia article on follistatin covers its structure, its high-affinity antagonism of activins and other transforming growth factor-beta family proteins, and its physiological roles, providing background on the molecule that Sh-Polypeptide-86 reproduces.

Examine

A direct search of examine.com for Sh-Polypeptide-86 and for follistatin returned no dedicated article. Examine.com focuses on orally-dosed dietary supplements and nutrients and does not cover topical cosmetic peptides such as this ingredient.

ConsumerLab

A direct search of consumerlab.com for Sh-Polypeptide-86 and for follistatin returned no results. ConsumerLab tests and reviews consumer dietary supplements and does not cover topical cosmetic peptide ingredients, so no article exists.

Systematic Reviews

No systematic reviews or meta-analyses for Sh-Polypeptide-86 were found on PubMed as of August 4, 2026.

Mechanism of Action

Sh-Polypeptide-86 is the cosmetic-ingredient name (under the International Nomenclature of Cosmetic Ingredients, INCI) for a synthetic version of human follistatin. Follistatin is a secreted protein whose main job is to bind and neutralize members of the transforming growth factor-beta (TGF-β; a large family of cell-signaling proteins) superfamily — chiefly activin (a growth-regulating signal protein), several bone morphogenetic proteins (BMPs; signals that, inside the follicle, help hold hairs in a resting state), and myostatin (also called GDF-8, the main brake on muscle growth).

The proposed hair-growth pathway runs through this braking action. In the hair follicle, the dermal papilla (the cluster of cells at the base of the follicle that directs the hair) produces activin, while BMP signaling helps keep follicles in their resting (telogen) phase. By mopping up activin and BMPs, follistatin is thought to release the follicle from these “stay dormant” signals and tip the balance toward the active growing (anagen) phase, encouraging matrix-cell proliferation and thicker hair shafts. Follistatin is also a natural marker of the follicle “bulge,” the reservoir of stem cells that regenerate the follicle with each cycle.

There are competing mechanistic views on both sides. Supporting topical use: animal work shows follistatin protein stimulates follicle development and that its removal retards follicle formation, and a follistatin-containing injected mixture increased hair density in an early human study. Arguing against a straightforward benefit: BMP signaling in dermal papilla cells is actually required for those cells to retain their hair-inducing ability, so broadly blocking BMPs could impair, not help, follicle function. A second, practical objection is delivery — follistatin is a large glycoprotein of roughly 34–38 kilodaltons (kDa; a unit of molecular weight), far above the size that readily crosses intact skin, so whether a meaningful amount reaches the follicle from a topical serum is unresolved.

Key pharmacological properties as a protein therapeutic:

  • Isoforms and selectivity: Two natural forms exist — FS-288, which binds tightly to cell surfaces via heparan-sulfate, and the longer circulating FS-315. Follistatin binds activin with very high affinity and also binds myostatin, GDF-11 (growth/differentiation factor 11, a related muscle- and tissue-growth regulator), and select BMPs; it is highly selective for these TGF-β-family ligands.

  • Half-life: Circulating follistatin is cleared quickly, with a systemic half-life on the order of hours (shorter for the cell-surface-bound FS-288). It is not orally bioavailable.

  • Tissue distribution: As a natural protein it is widely expressed (skin, muscle, ovary, liver); topically applied, its distribution is expected to be largely confined to the outer skin layers because of its size.

  • Metabolism: Being a protein, it is broken down by tissue proteases into peptides and amino acids and does not depend on liver cytochrome P450 (CYP; the enzyme family that metabolizes most small-molecule drugs) enzymes.

Historical Context & Evolution

Follistatin was first isolated in the 1980s from ovarian follicular fluid, named for its ability to suppress the release of follicle-stimulating hormone. Its original scientific interest was in reproduction and, later, in muscle biology, where its capacity to block myostatin made it a target for muscle-wasting diseases and, controversially, for performance enhancement.

The hair connection emerged from developmental biology in the late 1990s and early 2000s, when researchers mapping the signals that build and cycle hair follicles found that activin and BMP restrain follicle activity and that follistatin, by opposing them, promotes follicle development. This positioned follistatin as one of several “pro-anagen” factors of potential cosmetic and therapeutic interest.

The reason it came to be considered for hair optimization is largely translational and commercial. A bioengineered mixture of wound-healing and stem-cell signals that included follistatin was tested by injection in an early human hair-loss study, and the broader “growth factor” serum category then adopted follistatin as a marquee ingredient. Its recent prominence owes much to its inclusion in multi-peptide scalp serums promoted within longevity and self-experimentation communities, which brought the INCI label Sh-Polypeptide-86 to consumer attention.

The early findings have not been overturned, but neither have they been confirmed for topical use. The developmental biology remains well supported; what changed is the recognition that the single positive human study used injection of a multi-factor cocktail rather than a topical single ingredient, and that delivering a large protein through the scalp is a genuine and still-unsolved obstacle. The current standing is best described as biologically plausible but clinically unproven.

Expected Benefits

The benefits below are graded by the strength of evidence for Sh-Polypeptide-86 as a hair-regrowth ingredient specifically. No benefit reaches High or Medium: the single supportive human trial used an injected, multi-factor complex rather than a topical single ingredient, so all direct evidence for this ingredient is Low or Speculative.

Low 🟩

Increased Terminal Hair Density

The most tangible benefit is an increase in the number of thick, pigmented “terminal” hairs in a treated area. The proposed mechanism is release of resting follicles into the growing phase through activin/BMP inhibition. The evidence basis is a single small phase-1 randomized controlled trial (RCT; a study in which participants are randomly assigned to treatment or placebo) of an injected follistatin- and Wnt-containing complex (Wnt being a developmental signaling pathway that helps switch hair follicles into their growing phase), not of a topical serum, and the follistatin contribution cannot be isolated from the other factors. This trial was funded and conducted by the company that commercialized the product (Histogen), a direct financial conflict of interest that should temper how much weight the positive result carries. It is graded Low because the only positive human signal is indirect, involves a different delivery route, and has not been replicated for a topical product.

Magnitude: In the phase-1 trial of the injected complex, terminal hair density rose about 20.6% versus 4.4% for placebo at 12 weeks; no magnitude has been established for topical Sh-Polypeptide-86 alone.

Increased Hair Shaft Caliber

Beyond raw counts, follistatin-associated treatment has been linked to thicker individual hair shafts, which improves the perception of fullness. The proposed mechanism is enhanced matrix-cell proliferation during a lengthened growing phase. The evidence again derives from the same injected-complex trial, which measured shaft thickness directly; no topical monotherapy data exist, and small sample sizes limit confidence.

Magnitude: Hair shaft thickness increased roughly 6.3% versus placebo (about −0.6%) at 12 weeks in the injected-complex trial; not quantified for topical Sh-Polypeptide-86 alone.

Speculative 🟨

Anagen Prolongation via Activin and BMP Inhibition

By sequestering activin and BMPs, follistatin could, in principle, extend the growing phase and delay the regression phase of the hair cycle, a change that would increase hair length and density over time. This rests on animal and cell studies of the follicle cycle rather than on controlled human data. In humans applying a topical serum, whether enough intact protein reaches the follicle to shift cycle timing is unknown, so the basis is mechanistic only.

Hair Follicle Neogenesis

A more ambitious possibility is that follistatin contributes to the formation of entirely new follicles, as suggested by rodent wound-induced hair neogenesis models in which follistatin is among the factors that improve follicle-forming (“trichogenic”) activity. No evidence supports de novo follicle formation from a topical human serum; the basis is animal and in vitro work only.

Reduced Perifollicular Fibrosis

Because follistatin antagonizes transforming growth factor-beta signaling, which drives tissue scarring, it is speculated to soften the perifollicular fibrosis that accompanies advanced pattern hair loss and may lock follicles out of the cycle. This is a purely mechanistic extrapolation with no direct hair-specific human or animal data, and is therefore anecdotal/mechanistic only.

Benefit-Modifying Factors

  • Genetic androgen sensitivity: Pattern hair loss is driven largely by inherited follicle sensitivity to dihydrotestosterone (DHT; the potent androgen that miniaturizes follicles). A follistatin serum does nothing to lower DHT, so individuals whose loss is strongly androgen-driven may see little benefit without a DHT-directed therapy alongside it.

  • TGF-β/BMP pathway variation: Because the proposed mechanism runs through activin and BMP signaling, inherited differences in these pathways could plausibly make some follicles more or less responsive, though no validated genetic marker of response exists.

  • Baseline degree of miniaturization: Follicles that are thinning but still cycling are more likely to respond than follicles that are already fully dormant or scarred. Areas of early, diffuse thinning are the most plausible responders.

  • Baseline biomarker status: Low iron stores (ferritin), low vitamin D, and untreated thyroid dysfunction independently impair hair growth; benefit is more likely when these are corrected, as they can otherwise cap any follicle-level effect.

  • Sex-based differences: The one supportive human study enrolled men with androgenetic alopecia (AGA; the common male- and female-pattern hair loss). Female pattern loss differs in hormonal drivers and pattern, so benefit cannot be assumed to transfer equally between sexes.

  • Pre-existing scalp conditions: Scarring alopecias destroy the follicle and its stem-cell niche; a pro-growth signal cannot regenerate a follicle that no longer exists, so these individuals should not expect benefit.

  • Age: Older follicles accumulate reduced stem-cell activity and greater fibrosis; those at the older end of the target range may respond less robustly than younger adults with early thinning.

Potential Risks & Side Effects

Topical peptide serums are generally well tolerated, and no serious risks are established for Sh-Polypeptide-86 specifically. The concerns below are graded accordingly, with the theoretical proliferation and systemic issues clearly separated from the modest, well-documented irritation risks.

Low 🟥

Application-Site Irritation and Contact Dermatitis

The most common issue with any leave-on scalp serum is local irritation — redness, stinging, dryness, or an itchy rash — driven not necessarily by the peptide but by solvents, preservatives, and other actives in the formula. It is usually mild, appears early, and resolves on stopping the product. Sensitivity varies by individual and rises when the serum is layered with other irritating actives such as retinoids or exfoliating acids.

Magnitude: Mild irritation is reported in a small minority of users of cosmetic scalp serums, on the order of a few percent; severe reactions are rare.

Scalp Folliculitis and Pruritus

Leave-on serums applied daily to the scalp can occasionally provoke folliculitis (inflammation of the follicle openings, seen as small itchy bumps) or persistent itching, particularly if the scalp is occluded or the product is combined with microneedling using non-sterile technique. It is typically self-limited and managed by pausing use and improving hygiene.

Magnitude: Not quantified in available studies.

Speculative 🟨

Theoretical Tumor-Promoting Potential

Because follistatin lifts natural brakes (activin, BMPs) on cell proliferation and is combined in some serums with other growth factors, a theoretical concern is that chronic local growth-factor stimulation could promote the growth of pre-existing skin lesions. Reassuringly, biopsies in the injected-complex human trial showed no abnormal growths at up to one year, but topical long-term data are absent, so the concern remains hypothetical rather than demonstrated.

Systemic Myostatin and Activin Effects with Absorption

Follistatin’s systemic actions include blocking myostatin and altering activin-dependent hormone signaling. If a topical serum delivered meaningful amounts into the bloodstream, effects outside the scalp would be conceivable. In practice, the protein’s large size makes significant systemic absorption from intact skin unlikely, and no such effects have been reported; this is a mechanistic concern only.

Immunogenicity and Unknown Long-Term Safety

As a bioengineered protein applied repeatedly, Sh-Polypeptide-86 could in theory provoke local immune recognition or allergic sensitization over time, and its multi-year safety profile is simply unstudied. No signal has been reported, but the absence of long-term data is itself a limitation rather than reassurance.

Risk-Modifying Factors

  • Genetic and enzymatic variation: No pharmacogenetic variant is known to modify the safety of a topical protein that is not metabolized by liver enzymes; drug-metabolism polymorphisms are largely irrelevant here.

  • Baseline biomarker status: There is no established blood marker that predicts adverse response. A baseline skin exam matters more than any lab value for flagging pre-existing scalp lesions that warrant caution.

  • Sex-based differences: No sex-specific safety differences are documented for topical use. The theoretical hormonal (activin/follicle-stimulating hormone) considerations of systemic follistatin are not expected to apply to a topical serum in either sex.

  • Pre-existing conditions: A personal history of skin cancer or suspicious scalp lesions raises the theoretical proliferation concern; active scalp dermatitis, eczema, or infection increases both irritation risk and absorption through a compromised barrier.

  • Age: Older adults tend to have thinner, more reactive skin and a higher background rate of scalp lesions, modestly raising both irritation and the theoretical proliferation concern at the older end of the target range.

  • Barrier integrity: Broken, inflamed, or freshly microneedled skin increases absorption and infection risk, effectively amplifying every other concern; intact skin is the lowest-risk state.

Key Interactions & Contraindications

  • Topical hair-loss drugs (minoxidil, finasteride, topical): No adverse interaction is known; these are commonly layered with peptide serums. Severity: monitor. Consequence: none expected, but overlapping application can increase scalp irritation. Mitigation: separate application by several minutes and reduce frequency if irritation appears.

  • Topical retinoids and exfoliating acids (tretinoin, adapalene, glycolic/salicylic acid): These raise skin permeability and irritation. Severity: caution. Consequence: increased stinging, redness, and potentially greater peptide absorption. Mitigation: apply at a different time of day or on alternate days.

  • Over-the-counter scalp products (medicated shampoos, benzoyl peroxide, alcohol-based tonics): Severity: caution. Consequence: additive dryness and irritation; oxidizing agents may degrade the peptide. Mitigation: rinse and dry the scalp before applying, and avoid immediate layering with peroxide products.

  • Supplement and additive-effect considerations: No systemic supplement interactions are expected for a topically applied protein. Supplements that independently support hair (iron in the iron-deficient, vitamin D, biotin) do not interact adversely and may address separate limiting factors, but they do not potentiate the peptide directly.

  • Microneedling and injectable “mesotherapy” use: Severity: caution. Consequence: deliberately breaching the skin barrier raises infection risk and unpredictable absorption of a non-sterile cosmetic serum. Mitigation: do not use a cosmetic-grade serum for needling; only sterile, purpose-made products under professional guidance.

  • Populations who should avoid or defer use: Pregnant or breastfeeding individuals (no safety data); anyone with a personal history of scalp or skin cancer or an undiagnosed suspicious scalp lesion (until evaluated), given the theoretical proliferation concern; and anyone with active scalp infection, open wounds, or a scarring alopecia (no benefit, higher risk). Severity: relative contraindication in these groups. Consequence: unknown fetal/neonatal exposure, possible stimulation of a lesion, or worsened infection.

Risk Mitigation Strategies

  • Patch test before scalp-wide use: Apply a small amount to the inner forearm or a small scalp area daily for 3–5 days and check for rash before broader use. This mitigates contact dermatitis and allergic sensitization by catching a reaction while it is small.

  • Apply only to intact, healthy skin: Avoid broken, sunburned, freshly shaved, or inflamed scalp. Keeping application to an intact barrier limits both excess absorption and the folliculitis/infection risk.

  • Space out irritating actives: Keep at least several hours (ideally a different time of day) between the serum and retinoids, exfoliating acids, or benzoyl peroxide. This directly reduces the additive irritation and dryness identified as the most common side effect.

  • Do not combine with home microneedling: Reserve any barrier-breaching technique for sterile, professionally supervised products. This mitigates the infection and unpredictable-absorption risks tied to breaching the skin.

  • Stop at the first sign of a spreading rash or itch: Discontinue and allow the scalp to recover; reintroduce only cautiously if at all. Early cessation prevents a minor irritation from progressing to a persistent dermatitis.

  • Get suspicious scalp lesions evaluated first: Have any changing mole or non-healing spot on the scalp checked by a clinician before starting, which addresses the theoretical tumor-promotion concern by removing at-risk lesions from the treatment field.

Therapeutic Protocol

Because no regulator has approved Sh-Polypeptide-86 for hair growth, there is no validated dosing standard; the protocols below reflect how the ingredient is actually used in consumer and clinical settings.

  • Standard consumer use (leading practice): As popularized in multi-peptide “peptide serum” stacks within the longevity community, the serum is applied once daily — typically 1 to a few dropper-fulls — to a clean, dry scalp in the thinning area, massaged in and left on. Consistency over at least 4 months is emphasized as more important than dose.

  • Competing approach — injected multi-factor complex: A separate, clinic-based strategy delivers follistatin as one component of an injected “hair stimulating complex” of wound-healing and stem-cell factors, given as intradermal injections by a practitioner rather than as a daily topical. This is the approach that generated the only supportive human trial data and is presented here as the main alternative, without framing either route as the default.

  • Originating groups: The injected-complex approach was developed and popularized by the biotechnology company Histogen (San Diego) building on the work of Naughton and colleagues; the daily topical peptide-stack approach was popularized more recently through consumer longevity programs.

  • Best time of day: No circadian advantage is established. Once-daily evening application on a dry scalp is common simply to avoid wash-off and to fit grooming routines.

  • Expected half-life / dosing rationale: Circulating follistatin’s half-life is only hours, but topical dosing rationale is driven by residence time in the skin, not blood levels; this is why daily reapplication rather than a long-acting schedule is used.

  • Single vs. split dosing: A single daily application is standard; there is no evidence that splitting into multiple daily applications improves outcomes, and more frequent use mainly raises irritation risk.

  • Genetic considerations: No pharmacogenetic marker (for example, variants in androgen or TGF-β pathways) is validated to guide dose or selection; individuals with strongly androgen-driven loss typically need a DHT-directed therapy in parallel.

  • Sex-based considerations: Human supportive data derive from men; women with pattern loss may use the serum but should recognize the evidence does not yet extend to them and that hormonal drivers differ.

  • Age considerations: Older adults with early thinning may still apply the standard protocol but should expect a smaller effect and monitor thin, reactive scalp skin for irritation.

  • Baseline biomarker considerations: Correcting low ferritin, low vitamin D, and thyroid dysfunction before or alongside use removes common ceilings on any hair-growth response.

  • Pre-existing conditions: Those with scarring alopecia, active scalp disease, or suspicious lesions should have these addressed first, as they alter both the likelihood of benefit and the safety profile.

Discontinuation & Cycling

  • Lifelong vs. short-term: Like other maintenance hair treatments, any benefit is presumed to depend on continued use; there is no evidence of a lasting “cure” after stopping, so the realistic model is ongoing use.

  • Withdrawal effects: No withdrawal syndrome is described. The expected consequence of stopping is a gradual loss of any gained hairs over subsequent cycles, as seen when other pro-growth treatments are discontinued, rather than an acute shed or rebound.

  • Tapering: Because there is no physical dependence or systemic exposure, no tapering schedule is needed; the product can simply be stopped.

  • Cycling: No cycling regimen has been studied or shown to maintain or restore efficacy. There is no mechanistic reason to expect tolerance to a topically applied signaling protein, so routine cycling is neither established nor clearly rational.

  • Practical framing: Users should treat it as a continuous cosmetic routine with the understanding that gains, if any, are maintained only while use continues.

Sourcing and Quality

  • Product category: Sh-Polypeptide-86 is sold as a cosmetic ingredient within leave-on serums, not as a standalone supplement or drug; quality therefore hinges on the formulation and manufacturer rather than on a monograph standard.

  • What to look for: Prefer products that disclose the peptide’s concentration or position in the ingredient list, use a full INCI ingredient declaration, and come from brands that publish stability and manufacturing information. Bioactive proteins degrade with heat, light, and oxidation, so look for airless or opaque packaging and any cold-chain or shelf-life guidance.

  • Third-party testing: Because cosmetic peptides are not routinely verified, independent testing for identity, purity, and microbial contamination is a meaningful differentiator; favor brands that provide a certificate of analysis or third-party test results.

  • Reputable sources: Established peptide-serum brands and multi-peptide “growth factor” formulations from companies that document sourcing are preferable to unbranded research-chemical suppliers. For the injected-complex route, only clinician-administered, purpose-manufactured products (as used in the clinical studies) are appropriate — never self-injection of cosmetic serums.

  • Red flags: Avoid products making explicit drug-like regrowth claims (a regulatory violation and a marketing warning sign), those with no batch or expiry information, and any encouragement to inject or needle a cosmetic-grade serum.

Practical Considerations

  • Time to effect: Hair cycles are slow; any visible change would take at least 3–4 months of consistent daily use, with 6 months a more realistic assessment point, mirroring the timeline of other hair treatments.

  • Common pitfalls: Expecting drug-level results from an unproven cosmetic ingredient; stopping after a few weeks; ignoring the large-protein delivery problem; layering it with harsh actives that cause irritation; and neglecting correctable drivers of shedding such as low iron or thyroid issues.

  • Regulatory status: As a cosmetic ingredient, Sh-Polypeptide-86 may be sold in leave-on products but cannot be legally marketed with drug claims to treat hair loss; it is not a U.S. Food and Drug Administration (FDA)-approved hair-loss treatment. The injected hair-stimulating complex remains investigational and is not an approved therapy.

  • Cost and accessibility: Peptide “growth factor” serums are typically expensive relative to established options, and the ingredient is easy to obtain in cosmetic form but has no insurance coverage; the clinic-based injected approach, where offered, is considerably costlier and not widely available.

  • Realistic expectations: It is best positioned, if used at all, as an experimental add-on to evidence-based measures rather than a replacement for them.

Interaction with Foundational Habits

  • Sleep: The interaction is indirect. Poor sleep elevates stress signaling that can push follicles into shedding, so inadequate sleep may blunt any benefit; there is no evidence the serum affects sleep in either direction. Practical point: address chronic sleep loss as a background condition rather than expecting the serum to override it.

  • Nutrition: The interaction is indirect and potentially limiting. Hair growth depends on adequate protein, iron, zinc, and vitamin D, and deficiencies cap follicle output regardless of any topical signal. There is no known food that potentiates or degrades the serum once applied; the practical step is to correct nutritional shortfalls (especially iron in menstruating individuals) so they do not mask a response.

  • Exercise: The interaction is largely indirect. Exercise transiently raises circulating follistatin and influences myostatin systemically, but a scalp serum acts locally and this systemic shift is unlikely to add to or blunt topical effects. There is no timing requirement around workouts; sweat and scalp oil are reasons to apply to a clean, dry scalp after exercise rather than before.

  • Stress management: The interaction is indirect. Sustained stress raises cortisol and can trigger diffuse shedding (telogen effluvium) that works against any pro-growth aim, so stress reduction supports the same goal. The serum is not known to affect the stress response; practically, managing a major stressor is more impactful for shedding than the serum itself.

Monitoring Protocol & Defining Success

Because this is an unproven cosmetic ingredient, monitoring centers on tracking hair change objectively and on excluding correctable medical drivers of hair loss rather than on drug-safety labs.

Baseline assessment should be done before starting: standardized, same-lighting photographs of the thinning areas (and, where available, a trichoscopy or hair-count image), plus a screen for common reversible contributors to shedding. This establishes a reference point that memory alone cannot provide.

Ongoing monitoring is best done on a fixed cadence: reassess photographs at about 3 months and 6 months, then every 6 months, since hair change is too slow to judge sooner; repeat blood markers only if baseline values were abnormal or symptoms change.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Ferritin (iron stores) 40–70 ng/mL Low iron stores are a common, correctable cause of shedding that can mask any benefit Ferritin is an acute-phase protein and rises with inflammation; pair with hs-CRP (high-sensitivity C-reactive protein, a blood marker of inflammation) if a value looks falsely high. Conventional “normal” starts near 15 ng/mL, well below the hair-relevant threshold
Vitamin D, 25-hydroxy (25-OH-D) 40–60 ng/mL Low vitamin D is associated with hair shedding and follicle cycling problems 25-OH-D is the storage form measured for status; standard labs may flag deficiency only below 20 ng/mL, lower than the functional target
Thyroid-stimulating hormone (TSH) 0.5–2.5 mIU/L Both under- and over-active thyroid cause diffuse hair loss that mimics or masks pattern loss Best drawn in the morning; if abnormal or symptomatic, add free thyroxine (free T4) and thyroid antibodies
Total and free testosterone Mid-normal for age and sex Helps contextualize androgen-driven loss, which a follistatin serum does not address Draw in the morning when androgens peak; free testosterone reflects the biologically active fraction
Dihydrotestosterone (DHT) Sex-appropriate reference The main androgen driving follicle miniaturization; frames whether a DHT-directed therapy is also needed Optional; most useful when considering or monitoring a DHT-lowering treatment alongside the serum

Qualitative markers to track alongside the labs and photos:

  • Daily hair shedding (for example, hairs in the shower or on the pillow) trending down or stabilizing
  • Subjective scalp coverage and “fullness,” especially at the hairline and crown
  • Hair caliber — whether regrowth comes in as thin, wispy hairs or thicker, pigmented ones
  • Scalp comfort — absence of persistent redness, itching, or bumps, which would signal an irritation problem rather than success

Emerging Research

Content here is framed for a proactive reader weighing an early-stage ingredient, and deliberately includes directions that could weaken the case as well as strengthen it.

  • Follistatin-containing hair-stimulating complex trial: The clearest ongoing/registered clinical signal is a company-sponsored study of an injected hair-stimulating complex containing follistatin and related factors in men with androgenetic alopecia — a phase 1/2 trial of 56 participants evaluating safety and hair-growth efficacy (NCT01501617). Its results would speak to the injected-complex route rather than to topical serums.

  • Foundational efficacy evidence to build on: The single supportive human study — a first-in-man phase 1 RCT of the injected Wnt- and follistatin-containing complex reporting increased terminal hair density at 12 weeks and sustained hair count at one year (Zimber et al., 2011) — remains the anchor that larger, topical, and better-controlled studies would need to reproduce or refute.

  • Follicle-neogenesis biology (could strengthen): Work identifying follistatin among the factors that improve follicle-forming activity in regeneration models (Bak et al., 2015) points to a research direction — deliberately harnessing follistatin for new-follicle formation — that could expand its role if translated to humans.

  • Topical-delivery research (could weaken or enable): The central open question is whether a large protein can reach the follicle from a serum at all. Advances in penetration enhancers, microneedle patches, and nanocarrier delivery could make topical use viable, while continued failure to demonstrate meaningful delivery would undercut the entire consumer category. Follicle stem-cell mapping that established follistatin as a bulge marker (Ohyama et al., 2006) informs where such delivery would need to act.

  • Counter-signal to watch (could weaken): Evidence that BMP signaling is required for dermal papilla cells to retain hair-inducing capacity raises the possibility that broad activin/BMP inhibition is a double-edged sword, and future mechanistic studies could show a net-neutral or adverse follicle effect for indiscriminate follistatin exposure.

Conclusion

Sh-Polypeptide-86 is a lab-made copy of follistatin, a natural protein that blocks several “stop growing” signals in the hair follicle. On paper this is an appealing target: releasing those brakes could, in theory, wake resting follicles and thicken hair. The biology that inspired its use is genuinely well supported in animal and cell studies, and one small early human study of an injected mixture that included it showed real, if modest, increases in hair thickness and density.

The gap between that promise and everyday use is wide. The only supportive human evidence comes from an injected blend of several factors, not from the daily scalp serums that now feature this ingredient, so the specific contribution of follistatin applied to the skin is unproven. That single positive result also came from a study funded by the company selling the product, a financial conflict of interest that weakens its weight further. A practical obstacle compounds the uncertainty: the protein is large and does not easily cross intact skin, leaving real doubt that a serum delivers a useful amount to the follicle. Safety in short-term cosmetic use appears limited to mild scalp irritation, but long-term data are absent and a few theoretical concerns remain open.

Taken together, the picture is one of plausible biology and thin clinical proof. This review lays out what is known and unknown so that interest, which currently runs well ahead of the evidence, can be weighed against how little has actually been shown.

Top - Benefits - Risks - Protocol